Why Oscar Health (OSCR) Stock Is Down Today

Oscar Health (OSCR) is down 3.3% today. Here is some analysis on what might have caused this price movement. ([ir.oscarhealth.com](https://ir.oscarhealth.com/news-events/press-releases/detail/225/oscar-health-announces-thrive-capitals-completion-of-oscar-health-common-stock-distribution-to-its-limited-partners?utm_source=openai))

Analysis: The most likely driver is a fresh supply overhang after Oscar disclosed that funds affiliated with its majority stockholder, Thrive Capital, distributed about 6.3 million Class A shares to limited partners on September 18, 2026. This looks more like a technical pressure event than a deterioration in Oscar’s operating outlook, since the company had just raised full-year 2026 guidance at its Investor Day a few days earlier. ([ir.oscarhealth.com](https://ir.oscarhealth.com/news-events/press-releases/detail/225/oscar-health-announces-thrive-capitals-completion-of-oscar-health-common-stock-distribution-to-its-limited-partners?utm_source=openai))

Details:

Oscar announced that Thrive-affiliated funds completed a pro rata distribution of roughly 6.3 million Class A shares to their limited partners. ([ir.oscarhealth.com](https://ir.oscarhealth.com/news-events/press-releases/detail/225/oscar-health-announces-thrive-capitals-completion-of-oscar-health-common-stock-distribution-to-its-limited-partners?utm_source=openai))

The company said the distribution was an in-kind return of capital and not a sale of shares by Thrive Capital or Joshua Kushner, but the added float can still weigh on trading. ([ir.oscarhealth.com](https://ir.oscarhealth.com/news-events/press-releases/detail/225/oscar-health-announces-thrive-capitals-completion-of-oscar-health-common-stock-distribution-to-its-limited-partners?utm_source=openai))

Just before that disclosure, Oscar told investors at its September 16, 2026 Investor Day that it was improving full-year guidance for medical loss ratio and earnings from operations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1568651/000156865126000074/oscr-20260916.htm?utm_source=openai))

Oscar’s longer-term targets presented at Investor Day pointed to continued revenue growth and margin expansion, which suggests today’s drop could be profit-taking or supply-related rather than a reaction to weaker fundamentals. ([oscarhealth.com](https://oscarhealth.com/news/oscar-health-building-new-consumer-health-economy?utm_source=openai))

Sources:

Oscar Health Investor Relations, SEC, StockAnalysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$OSCR Insider Trading Activity

$OSCR insiders have traded $OSCR stock on the open market 45 times in the past 6 months. Of those trades, 1 have been purchases and 44 have been sales.

Here’s a breakdown of recent trading of $OSCR stock by insiders over the last 6 months:

MARK T BERTOLINI (Chief Executive Officer) has made 1 purchase buying 1,000,000 shares for an estimated $11,920,000 and 8 sales selling 2,445,306 shares for an estimated $70,679,399.
MARIO SCHLOSSER has made 0 purchases and 20 sales selling 1,890,542 shares for an estimated $56,226,781.
RICHARD SCOTT BLACKLEY (Chief Financial Officer) has made 0 purchases and 7 sales selling 289,302 shares for an estimated $7,267,548.
JANET LIANG (President, Oscar Insurance) has made 0 purchases and 3 sales selling 22,835 shares for an estimated $599,538.
ADAM MCANANEY (Chief Legal Officer) has made 0 purchases and 3 sales selling 18,951 shares for an estimated $502,261.
VICTORIA BALTRUS (Chief Accounting Officer) has made 0 purchases and 3 sales selling 2,481 shares for an estimated $63,545.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$OSCR Hedge Fund Activity

We have seen 252 institutional investors add shares of $OSCR stock to their portfolio, and 192 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 10,150,762 shares (+351.9%) to their portfolio in Q2 2026, for an estimated $289,499,732
D. E. SHAW & CO., INC. added 6,556,255 shares (+107.7%) to their portfolio in Q2 2026, for an estimated $186,984,392
FMR LLC added 3,799,751 shares (+317.0%) to their portfolio in Q2 2026, for an estimated $108,368,898
JANE STREET GROUP, LLC added 3,460,934 shares (+119.2%) to their portfolio in Q2 2026, for an estimated $98,705,837
RENAISSANCE TECHNOLOGIES LLC added 3,284,500 shares (+inf%) to their portfolio in Q2 2026, for an estimated $93,673,940
BLACKROCK, INC. added 3,277,889 shares (+18.9%) to their portfolio in Q2 2026, for an estimated $93,485,394
BIT CAPITAL GMBH removed 2,903,464 shares (-45.9%) from their portfolio in Q2 2026, for an estimated $82,806,793

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$OSCR Price Targets

Multiple analysts have issued price targets for $OSCR recently. We have seen 4 analysts offer price targets for $OSCR in the last 6 months, with a median target of $19.5.

Here are some recent targets:

Andrew Mok from Barclays set a target price of $35.0 on 06/10/2026
Michael Ha from Baird set a target price of $19.0 on 05/07/2026
Jonathan Yong from UBS set a target price of $20.0 on 05/07/2026
David Windley from Jefferies set a target price of $16.0 on 04/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.